Dr. Hsieh Discusses New Treatments for Kidney Cancer

James J. Hsieh, MD, PhD
Published: Friday, Apr 25, 2014

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

Emerging treatment options in this space are all trial based. The newer generation of antiangiogenic therapies have similar efficacy but are less toxic. Hsieh says mTOR inhibitors are also being improved.

There is also excitement surrounding immunotherapy in this space. Emerging immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

Emerging treatment options in this space are all trial based. The newer generation of antiangiogenic therapies have similar efficacy but are less toxic. Hsieh says mTOR inhibitors are also being improved.

There is also excitement surrounding immunotherapy in this space. Emerging immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x